Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract
• By Donna Young
Generate a summary of this article
Listen to this article
Takeda is officially in the ballgame, joining the ranks of other firms like Sanofi Pasteur and GlaxoSmithKline, to find a vaccine against the Zika virus after snagging a US government R&D contract worth up to $312m.
Takeda Pharmaceutical Co. Ltd. has jumped fully into development of a Zika vaccine after landing a US government contract worth up to $312m that will fund the Japanese biopharmaceutical firm's efforts.
Takeda has banked $19.8m from the US Biomedical Advanced Research and Development Authority (BARDA) to get the ball rolling on...
Keep up with the top pharma business news of the week. On the go.
PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.